Related Experiment Video

Updated: Aug 16, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.4K

[Antiastenic effect of sequential levocarnitine and acetylcarnitine therapy in patients with cardiovascular diseases]

M E Statsenko1, S V Turkina1

  • 1Volgograd State Medical University, Volgograd, Russia.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|December 20, 2022
PubMed

Insights

Sequential therapy with levocarnitine (LC) and acetylcarnitine (ALC) effectively reduced asthenic syndrome (AS) in patients with cardiovascular disease. This treatment also demonstrated endothelium-protective effects, improving patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Neurology

Context:

  • Asthenic syndrome (AS) is a common complication in patients with arterial hypertension and/or coronary heart disease (CHD).
  • Fatigue significantly impacts quality of life and treatment adherence in cardiovascular patients.
  • Limited therapeutic options exist for managing asthenia in this population.

Purpose:

  • To evaluate the antiasthenic efficacy of a sequential therapy combining levocarnitine (LC) and acetylcarnitine (ALC).
  • To assess the impact of this sequential therapy on asthenic syndrome (AS) in patients with arterial hypertension and/or coronary heart disease (CHD).
  • To investigate the endothelium-protective effects of LC and ALC in this patient group.

Summary:

  • An open comparative study involved 120 patients with arterial hypertension and/or CHD experiencing AS.
  • Group 1 received 10 days of intravenous LC followed by 2 months of oral ALC, alongside basic therapy.
  • Group 2 received only basic therapy. Asthenia was assessed using the MFI-20 and VAS-A scales.
  • Group 1 showed a statistically significant reduction in AS manifestations compared to baseline and Group 2.
  • LC and ALC demonstrated endothelium-protective effects.

Impact:

  • Sequential LC and ALC therapy significantly reduces asthenic syndrome severity in comorbid cardiovascular patients.
  • The established endotheliotropic properties support the use of LC and ALC in personalized cardiovascular disease management.
  • This therapeutic approach offers a novel strategy to improve the quality of life for patients with cardiovascular diseases and asthenia.
Abstract

Keywords:
CarnicetineElcaracetylcarnitinecardiovascular diseasesendothelial dysfunctionlevocarnitinemoderate cognitive deficit

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K
Author Spotlight: Enhancing Coronary Artery Revascularization05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

810

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
667
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
23
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
435
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
615
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
747